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Hospital healthcare workers (HCW) are at increased risk of contracting COVID-19 infection. 
We aimed to determine the seroprevalence of SARS-CoV-2 antibodies in HCW in Ireland. 
Two tertiary referral hospitals in Irish cities with diverging community incidence and 
seroprevalence were identified; COVID-19 had been diagnosed in 10.2% and 1.8% of staff 
respectively by the time of the study (October 2020).  All staff of both hospitals (N=9038) 
were invited to participate in an online questionnaire and blood sampling for SARS-CoV-2 
antibody testing. Frequencies and percentages for positive SARS-CoV-2 antibody were 
calculated and adjusted relative risks (aRR) for participant characteristics were calculated 
using multivariable regression analysis.  5,788 HCW participated (64% response rate).  
Seroprevalence of antibodies to SARS-CoV-2 was 15% and 4.1% in Hospital 1 and 2, 
respectively.  Thirty-nine percent of infections were previously undiagnosed. Risk for 
seropositivity was higher for healthcare assistants (aRR: 2.0, 95%CI:1.4–3.0), nurses (aRR: 
1.6, 95%CI: 1.1–2.2), daily exposure to patients with COVID-19 (aRR: 1.6, 95%CI: 1.2-2.1), 
age 18-29 years (aRR: 1.4, 95%CI: 1.1-1.9), living with other HCW (aRR: 1.3, 95%CI: 1.1–
1.5), Asian background (aRR: 1.3, 95%CI: 1.0-1.6), and male sex (aRR: 1.2, 95%CI 1.0-1.4). 
The HCW seroprevalence was six times higher than community seroprevalence. Risk was 
higher for those with close patient contact.  The proportion of undiagnosed infections call for 
robust infection control guidance, easy access to testing and consideration of screening in 
asymptomatic HCW. With emerging evidence of reduction in transmission from vaccinated 










Healthcare workers, and those they live with, are at increased risk of contracting COVID-19 
viral infection  (1) (2) (3).  Raised antibody levels to SARSCoV2 are an excellent indicator of 
COVID-19 infection (4).  To date there are no published literature on the seroprevalence of 
antibodies to SARS-CoV-2 infection in Irish Healthcare workers (HCW), but it is known 
from surveillance data that a high proportion of the COVID-19 cases notified were HCW (5).  
Understanding the transmission and potential immunity dynamics of SARS-CoV-2 in 
hospitals in Ireland is key to controlling this pandemic at national and hospital level and adds 
valuable information to the growing evidence base on the transmission patterns of COVID-19 
among HCW.   
Hospital 1 is a tertiary referral hospital in the south inner city of Dublin, the capital city of 
Ireland (population 1.2 million) and has almost 4,700 employees and just over 1000 beds.  
From March-May 2020 (first wave of the pandemic in Ireland, (6)) 9.6% of the staff of 
Hospital 1 tested positive for SARS-CoV-2 infection via polymerase chain reaction (PCR), 
and by the start of October (the start of the second wave of the pandemic in Ireland, (6)) 
10.2% of staff had tested positive by PCR.  Hospital 2 is a comparable tertiary referral 
hospital with almost 4400 employees and over 500 beds, located in Galway, in the West of 
Ireland (population 80,000); 1.8% of its HCW had a PCR-confirmed infection at some stage 
during the time-period from March-May 2020 and this remained at 1.8% until the start of 
October 2020. Hospital 1 is one of the largest acute hospitals in Dublin city; hospital 2 is the 
main acute hospital serving the city of Galway. Both hospitals received patients with 
COVID-19 infection throughout the first wave of the pandemic in Ireland, and breakdown by 
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ward and specialty is similar. The community incidence of COVID-19 infection in County 
Galway was significantly lower than in County Dublin during this time period, which 
covered the first wave of the pandemic in Ireland and the start of the second wave (6).  The 
community seroprevalence was also significantly lower in the West of Ireland as compared 
with the greater Dublin area; community seroprevalence was 3.1% for Hospital 1 and 0.6% 
for Hospital 2 in June 2020 (7) (8).  
The purpose of the study was to determine the prevalence of anti- SARS-CoV-2 antibodies in 
HCW in these two hospitals with diverging community and healthcare rates of infection to 
improve understanding of HCW risk factors (demographic, living arrangements and work-
related risks) for SARS-CoV-2 infection and to inform risk reduction activities and help 
health services to prepare for further waves of the pandemic.  The study will be repeated in 
April 2021 to assess changes in overall seroprevalence, changes in individual serostatus over 




This is a cross-sectional study of the seroprevalence of circulating antibodies to SARS-CoV-
2, carried out from 14th-23rd October 2020.  All staff members of both hospitals were invited 
to participate in an online self-administered consent process and online questionnaire, 
followed by blood sampling for SARS-CoV-2 antibody testing. Electronic consent and 
patient reported outcomes were captured using Castor; an eClinical platform that enables 
decentralized clinical trials (9).  Technical support and walk-in phlebotomy clinics were 
provided for participants who had difficulty with the online consent process.  Information 
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collected in the questionnaire included demographic information, contact details, place and 
type of work, level of contact with patients, previous COVID-19 symptoms and testing, 
history of close contact with a confirmed case of COVID-19 and living arrangements.  Blood 
samples were processed anonymously.  All samples were tested on two testing platforms; the 
Abbott Architect SARS -CoV-2 immunoglobulin (Ig)G assay and the Roche Elecsys anti-
SARS-CoV-2 immunoassay (10) (11) (12).  Samples with an index result in the Abbott 
manufacturers suggested positive and grayzone underwent additional testing in the National 
Virus Reference Laboratory (NVRL) using the Wantai SARS-CoV-2 AB ELISA distributed 
by Fortress Diagnostics (13).  A positive result on any of the three assays was considered a 
positive result.  Results were discussed in person with any participant who requested this. 
Statistical analysis 
Frequencies and percentages were calculated for sociodemographic, epidemiological, and 
clinical characteristics, including antibody results.  Characteristics of those with a positive 
SARS-CoV-2 antibody result were compared to those with undetectable antibody, using the 
chi-square test.  Univariate logistic regression was used to calculate relative risks along with 
their 95% confidence intervals to assess the association between SARS -CoV-2 antibody 
result and characteristics of the study participants.  Multivariable regression analysis was 
conducted to control for negative and positive confounding and to calculate adjusted relative 
risks (aRR). No explicit finite population correction or reweighting was carried out. All 
analyses were conducted in Stata 16 (StataCorp. 2019. College Station, TX: LLC) and R 
4.0.3 (R Core Team, 2020, www.R-project.org/). 
Results 
Participation rates and demographics 
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All staff working in both hospitals (9,038 people) were invited to participate in the study. In 
Hospital 1 and Hospital 2, 65% (3042/4692) and 63% (2745/4395) of staff participated in 
both questionnaire and blood sample, respectively. 
The socio-demographic characteristics of participants were similar in both hospitals.  
Seventy-seven percent were female, with a median age of 39.5 years (IQR 30.4-48.9); 5.1% 
of participants were >60 years of age. Regarding ethnicity, 77% of participants were white 
Irish, 10% Asian (13% in Hospital 1 and 7% in Hospital 2), 9.5% other white background 
(majority born in Poland, USA, UK), 2% African or any other black background.  Ninety-one 
percent of participants live with others, and 31% live with other HCW.  The majority (36%) 
of participants were nursing staff, 19% were allied health care staff, 17% medical/dental staff, 
13% administration staff, 7.5% general support staff, 5% healthcare assistants (HCA) and 2% 
other HCW, broadly reflecting the HCW breakdown of the hospital staff (Table 1a).  
Participation rates among staff groupings were also similar in both hospitals; nurses and HCA 
were slightly under-represented at 59% and 39% uptake respectively.  In all other groups 
participation rates were above 60%. 
Previous testing and COVID-19 related characteristics of the participants 
Hospital 1 staff had a higher percentage of previously confirmed COVID-19 infection; 9.6% 
of participants reported having tested positive at some stage by PCR compared to 2.7% of 
participants in Hospital 2 (Table 1b).  Table 1b highlights the COVID-19-related 
characteristics of the participants by hospital. 
Seroprevalence of antibodies to SARS-CoV-2 
In Hospital 1 the overall seroprevalence of antibodies to SARS-COV-2 was 15% (464/3042).  
Regarding the level of patient contact, the seroprevalence was 21% (108/510) in participants 
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reporting daily contact with patients with known or suspected COVID-19 infection (we 
defined this as the high-risk group), 17% (269/1611) in those who reported daily contact with 
patients without known or suspected COVID-19 infection (intermediate-risk group) and 9.5% 
(87/918) in those who reported little or no patient contact (low-risk group).  In Hospital 2 the 
overall seroprevalence of antibodies to SARS-COV-2 was 4.1% (112/2745); 7.1% (28/392) 
in the high-risk group, 4.6% (75/1634) in the intermediate-risk group and 1.3% (9/717) in the 
low-risk group. 
When looking at seroprevalence by role, the combined data for both hospitals showed the 
highest seroprevalence in HCAs, with 18 % of those participating in the study having 
detectable antibodies.  This was followed by nurses at 13% and medical/dental staff at 10%.  
The group with the lowest seroprevalence were the administration staff at 6%.  Figure 1 
shows the proportion of each staff group with detectable antibodies by hospital.  
SARS-CoV-2 antibody and previous diagnosis and symptoms 
Ninety-five percent (350/367) of those who had previously confirmed infection by PCR had 
detectable antibodies.  In total 227/576 (39%) of those with positive antibodies had not 
previously been diagnosed with COVID-19 infection; this represented 3.9% of all 
participants. While 63% (142/227) of these participants with a previously undiagnosed 
infection reported having had symptoms at some stage, it is impossible to know if these 
symptoms coincided with the time of undiagnosed infection.  Sixteen percent (90/576) of 
those with detectable antibodies had experienced no symptoms consistent with COVID-19. 
Risk factors for antibody positivity to SARS-CoV-2 
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Tables 2a and 2b show the prevalence of SARS-CoV-2 IgG antibodies by participant 
characteristics for both hospitals combined.  (For the prevalence of SARS-CoV-2 IgG 
antibodies by participant characteristics for the individual hospitals see Tables A-D, annex).  
On multivariable analysis of the combined hospital data the adjusted relative risk of 
detectable antibody was higher for the following characteristics: working in Hospital 1 (aRR 
3.7, 95% CI 3.0-4.5. p<.001), working as a HCA (aRR 2.0, 95% CI 1.4 – 3.0, p 0.001), 
working as a nurse (aRR 1.6, 95% CI 1.1 – 2.2, p 0.007), daily exposure to patients with 
confirmed or suspected COVID-19 infection (aRR 1.6, 95% CI 1.2-2.1, p 0.002), daily 
contact with patients not known or suspected to have COVID-19 infection (aRR 1.4, 95% CI 
1.1-1.8, p 0.008), age 18-29 years (aRR 1.4, 95% CI 1.1-1.9, p 0.006), living with others 
(aRR 1.5, 95% CI 1.0-2.1, p 0.048), living with other HCW (aRR 1.3, 95% CI 1.1 – 1.5, p 
0.007), being of Asian background (aRR 1.3, 95% CI 1.0-1.6, p 0.028) and male sex (aRR 
1.2, 95% CI 1.0-1.4, p = 0.046) (Table 3). (For multivariable analysis by hospital see Table A 
and Table F, annex). 
Discussion 
Overall seroprevalence 
The seroprevalence between Hospital 1 and Hospital 2 differed by four-fold, reflecting the 
difference in incidence and seroprevalence in the community in the two locations; the 
seroprevalence in both locations was six times the community seroprevalence (7) (8). A 
Swedish study found HCW seroprevalence to be three times higher than the community 
seroprevalence during the first wave of the pandemic (14). A Greek study found HCW 
seroprevalence to be between 10-22 times higher than the general population (15); his was 
attributed in part to insufficient use/ availability of PPE in the hospital setting.  Infection 
prevention and control (IPC) measures were the same in Hospital 1 and in Hospital 2 (based 
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on national guidelines) and there have been no issues with PPE availability in either of the 
hospitals involved in our study at any stage thus far during the pandemic. In both hospitals 
staff were re-deployed to improve the hospital’s capacity to deal with the outbreak, however 
staff were not deployed to areas that would have been outside of their scope of practice, and 
all staff had training on the correct use of PPE. The seroprevalence in Hospital 1 was similar 
to that found in a recent unpublished study in another hospital in the same city (16), 
suggesting that one of the main risks for infection in HCW is the community incidence; a 
higher community incidence means that HCW are more likely to be exposed by the nature of 
their work which involves direct contact with other people, both patients and other HCW. 
While this risk disproportionately affected those with closer patient contact, the risk to HCW 
was higher than in the community, even for those who reported little or no patient contact.  
The seroprevalence in both hospitals fell within the wide range  (1-45%) previously described 
in other studies (17) (18) (19) (20) (21) (15), and fell either side of the European estimate of 
8.5% from the meta-analysis published in November 2020 (22) .  
Previous symptoms and testing 
Five percent of participants with a previous PCR-confirmed COVID-19 infection did not 
have detectable antibodies. The manufacturers’ reported test sensitivity is >95% for each 
assay used (11) (12) (13) , so while some of these may be false negative results, it is also 
possible that these participants did not mount an antibody response following infection with 
COVID-19, or that they had antibody levels below the limits of detection of the test. We feel 
that a false positive PCR result is less likely, but also possible.  
In both hospitals, the seroprevalence was higher than the known PCR-confirmed diagnoses of 
COVID-19 infection of the same timeframe (15% vs 10% in Hospital 1, and 4.1% vs 1.8% in 
Hospital 2), and was also higher than the self-reported previous confirmed diagnoses (15% vs 
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9.6% in Hospital 1, 4.1% vs 2.7% in Hospital 2).  Sixteen percent of participants with 
positive antibodies reported never having experienced symptoms that were consistent with 
infection with COVID-19.  Thirty-nine percent of infections in our study were undiagnosed, 
even though both hospitals had onsite PCR testing available to HCW with symptoms or close 
contact with a confirmed case of COVID-19 from mid-March 2020.  It is likely that these 
undiagnosed HCW were working during the infectious period, with potential for onwards 
transmission to patients and other staff members if proper use of PPE and other infection 
prevention and control (IPC) measures were not strictly adhered to. This highlights the 
importance of early detection and reinforces the importance of clear messaging to HCW 
about not working when symptomatic. It also highlights the necessity for universal adherence 
to standard infection control precautions at all times, compliance with transmission-based 
precautions and appropriate use of PPE including face masks in the hospital setting, 
irrespective of symptoms (23).  This finding also supports the recommendation for screening 
of asymptomatic staff when a patient case of hospital-acquired infection, or hospital outbreak 
of infection with COVID-19 occurs (24). Mass serial screening of asymptomatic HCWs 
should be considered. This intervention has been shown to be effective in certain settings 
(25,26).  However, the frequency of testing that would be required to have a significant 
impact on transmission of infection from HCW has not been established, and other studies 
have found the impact of this intervention to be uncertain and the logistical challenges it 
poses to the health service are significant (27) (28) (29).   
Risk factors for antibody positivity 
The main risk factors identified to be significantly associated with SARS-CoV-2 antibody 
positivity were working in Hospital 1, being a HCA, being a nurse, performing roles 
associated with close patient contact (especially those working directly with COVID-19 
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patients), living with others, living with other HCW, being of Asian ethnicity, being aged 18-
29 years and being male.  Similar risk factors have also been identified in other studies, 
including the meta-analysis of European studies (22) (30) (31).  Those of Asian background 
had a higher risk than those of white Irish background.  This was a significant finding on 
MVA, with other factors including exposure accounted for. It is possible that there are other 
social factors relating to ethnicity that were not evaluated in our study and that are 
contributing to this risk.  Studies conducted in other countries have also found Black 
individuals to be at a higher risk, and many studies have found higher risk in combined 
BAME (Black, Asian and Minority Ethnic) groups. Black individuals in our study did have a 
higher overall seroprevalence at 19%, and a higher relative risk of antibody positivity, 
however this finding was not statistically significant on multivariate analysis, possible due to 
smaller number of Black participants compared to Asian participants Other studies have 
highlighted close patient contact as a risk factor for disease acquisition (32), including 
specifically the role of nurse or HCA (15) (31).  We found daily contact with patients with 
COVID-19 infection to carry a higher relative risk of antibody positivity with comparison to 
daily contact with patients without COVID-19 infection.  Studies have differed on this result; 
a German study showed a higher seroprevalence among the intermediate risk group with 
comparison to the high-risk group, potentially  due to less scrupulous adherence to infection 
control precautions including use of PPE on non-COVID wards (17). A Spanish study found 
no significant correlation between role or direct patient contact and antibody positivity, 
though community incidence was higher in their setting (18). 
Having a household contact is known to be a significant risk factor for disease acquisition 
(33).  In our study, living with others (and especially living with other HCW) was 
significantly associated with antibody positivity, which supports the theory that a proportion 
of the HCW contracting COVID-19 are doing so in their home environment. Other studies 
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have found some correlation between size of household and antibody positivity (18) but to 
the best of our knowledge ours is the first study to find a statistically significant correlation 
between living with other HCW and being antibody positive. 
Limitations 
Our study has several limitations.  Firstly, information on COVID-19 symptoms and test 
results were self-reported and thus could be biased.  Secondly, although the uptake rate of 
64% overall is good for an opt-in study, there may be a selection bias; it is possible that those 
who chose not to take part did so due to busier workload, for example, those working on a 
COVID-19 ward, and therefore with a higher risk of COVID-19 infection.  One of the main 
reasons for overall good recruitment was the incentive of each participant receiving their 
individual result.  This too may introduce a selection bias; those who already know that they 
have had COVID-19 infection may have been less interested in participating, as well as those 
who may have already had private antibody testing done elsewhere, which could lead to an 
under-estimate in the true seroprevalence.  Conversely, those who had a previously confirmed 
infection by PCR may have had more interest in participating to see if they had gained 
antibodies (and potential immunity).  Thirdly, although the communication strategy was an 
important part of the recruitment process, the study took part during our second wave of the 
pandemic, and therefore also relied heavily on engagement with IT platforms (email, 
messenger groups, hospital intranet) and less on face-to-face announcements. The online 
consent process, questionnaire, and blood test booking system risks exclusion of those who 
are less literate in information technology (IT).  This was identified as a potential limitation 
from the start, and attempts were made to mitigate this selection bias.  Multilanguage 
information and plain English were used, and groups identified as potentially at risk of 
exclusion on this basis were targeted directly for inclusion in the study, with small-group 
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sessions to aid consent and questionnaire completion and walk-in clinics for phlebotomy. In 
the fourth instance, in testing on two different platforms, we chose to prioritise sensitivity 
over specificity. However, the rate of discordant results was low, and unlikely to have had a 
significant effect on the results; there were only 21 samples with a positive result on the 
Abbott Architect assay that did not have a positive result on either the Roche Elecsys assay or 
the Wantai ELISA.  In the fifth instance, this population was surveyed in October, at the start 
of the second wave of the pandemic in Ireland.  A proportion of the HCW workforce in 
Ireland is transient, and the staff included in the study may not have worked in the same 
hospital during the first wave of the pandemic.  However, over 90% of participants in each 
hospital reported that had been working in the same hospital during the first wave of the 
pandemic.  And finally, even though the sample size was large, some covariate partners were 
small and thus rendered further analysis lacking in statistical power and precision (e.g. 
interactions terms or further stratified analysis). 
Conclusion and Recommendations 
The overall seroprevalence of antibodies to SARS-CoV-2 was 15% in Hospital 1 and 4.1% in 
Hospital 2, reflecting the difference in community incidence and seroprevalence in each area, 
and suggesting that the main risk factor for acquisition of COVID-19 infection in HCW is the 
local community incidence.  The HCW seroprevalence was six times the community 
seroprevalence in each area.  Specific risk factors for antibody positivity included being a 
HCA or nurse, daily contact with patients (especially those known or suspected to have 
COVID-19 infection), age 18-29 years, living with others, in particular living with other 
HCW, being of Asian background, and being male.  The degree of previously undiagnosed 
and asymptomatic infections highlights the need for ongoing universal adherence to infection 
control guidance including the use of appropriate PPE in the hospital setting, as well as the 
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importance of early case detection. It is essential that HCW have easy access to testing, even 
with mild or no symptoms.  As the national COVID-19 vaccination programme is rolled out, 
we expect that access to testing for HCW will still be critical.  Screening of asymptomatic 
HCW in the setting of hospital-acquired patient infection or outbreaks is important and 
regular screening of asymptomatic HCW needs to be considered depending on local 
epidemiology. 
This study is a unique comparison between two hospitals in areas of differing community 
incidence, in which IPC measures were the same.  It is the first study, to the best of our 
knowledge, to specifically delineate the relationship between living with other HCW and risk 
of antibody positivity.  This study is paramount in improving understanding of transmission 
dynamics and HCW risk factors (demographic, workplace- and household-related) in 
hospitals in Ireland.  The high proportion of undiagnosed infections underscores the 
importance of all interventions to reduce infection in the hospital setting. This bundle should 
include robust infection control guidance and adherence to that guidance, with scrupulous 
attention to standard and transmission-based precautions including the use of appropriate PPE 
in the hospital setting, easy access to testing for HCW and prompt outbreak investigation.  
This study will be crucial in informing the vaccination strategy and roll-out of HCW in 
Ireland. Emerging evidence of reduced transmission of infection by vaccine recipients (34) 
endorses prompt vaccination of all HCW. 
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Tables  
Table 1a. Participant characteristics by hospital and total number of participants 





  n % n % N  % 
Age groups 18-29 728 24 632 23 0.717 1,350 23 
30-39 831 27 785 29 1,617 28 
 40-49 793 26 722 26 1,515 26 
 50-59 532 18 468 17 1001 17 
 Over 60 158 5.2 146 5.3 304 5.3 
Sex Female 2,326 77 2,152 78 0.117 4,478 77 
 Male 716 24 592 22 1,308 23 
 Missing - - 1 0.04 1 0.02 
Ethnicity Irish  2,262 74 2,182 80 4,444 77 
 Any other white 
background 
267 8.8 284 10 <0.001 
<0.001 
551 10 
 Any Asian 
background 
393 13 184 7 577 10 
 Any African or 
black background 
65 2.1 48 1.8 113 2.0 
 Other 55 1.8 46 1.7 101 1.8 
 Missing - - 1 0.04 1 0.02 
Country of Ireland  2,182         72 2,091 76 4,273 74 







United Kingdom 152 5.0 192 7.0  344 5.9 
India 201         6.6 98 3.6  299 5.2 
Philippines 166 5.5 25 0.9  191 3.3 
 Poland 24 0.8 48 1.8  72 1.2 
 USA 22 0.7 38 1.4  60 1.0 
 Other  295 9.7 253 9.2  548 9.5 
         
Education Primary 27 0.9 2 0.1 <0.001 29 0.5 
 Secondary 420 14 264 10  684 12 
 Third level 1,300 43 1,245 45  2,545 44 
 Post-graduate 1,295 43 1,232 45  2,527 44 
 Missing - - 2 0.1  2 0.03 
Role Admin 454 15 349 13 <0.001 803 14 
 Medical/ 
dental 
460 15 522 19  982 17 
 Nursing/ 
midwifery 
1045 34 1,019 37  2064 36 
 Allied health 616 20 475 17  1012 19 
 General support 255 8.4 179 6.5  434 7.5 
 Health care 
assistant 
157 5.2 129 4.7  286 4.9 
 Other 55 1.8 72 2.6  127 2.2 
         
Lives with Alone 256 8.4 223 8.1 0.020 479 8.3 
Lives with 
 
With others 2,768 91.0 2,518 91.7  5,286 91.3 
Missing 18 0.6 4 0.2  22 0.4 





Yes 928 31 839 31 0.983 1,767 31 
Lives with 
HCW 
No 2,060 68 1,859 68  3,919 68 
Missing 54 1.8 47 1.7  101 1.8 
        
 












 (N=2,745) P -value* 
Total 
(N=5,788) 
  n % n % n % 
Contact of a COVID-
19 case 
Yes 1,185 39 519 19 <0.001 1,704 30 
No 1,847 61 2,224 81  4,071 70 
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Missing 10 0.3 2 0.1  12 0.2 
Setting of close 
contact 
Contact at work 1,039 88 456 88 0.916 1,495 88 
Contact outside of 
work 
146 12 63 12  209 12 
         




510 17 392 14 <0.001 902 16 
Contact with patients 
without COVID-19 
1,611 53 1,634 60  3,245 56 
No patient contact 918 30 717 26  1,635 28 
 Missing 3 0.1 2 0.1  5 0.1 
Previous COVID-19 
symptoms 
No symptoms 1,359 45 1,517 55 <0.001 2,876 50 
Had symptoms 1,683 55 1,228 45  2,911 50 
        
Severity No symptoms 1,359 45 1,517 55 <0.001 2,876 50 
 Only minor symptoms 1,214 40 945 34  2,159 37 
 Significant symptoms 442 15 259 9.4  701 12 
 Hospitalised 27 0.9 24 0.9  51 0.9 
         
Previous COVID-19 
PCR test 
Yes 1,685 55 1,093 40 <0.001 2,778 48 
No 1,353 45 1,650 60  3,003 52 
 Missing 4 0.1 2 0.1  6 0.1 
Previous positive 
COVID-19 PCR test  
Yes 292 9.6 75 2.7 <0.001 367 6.3 
No 2,746 90.3 2,668 97.2  5,414 93.6 
Missing 4 0.1 2 0.1  6 0.1 
 







Table 2a. Prevalence of SARS-CoV-2 antibodies by participant characteristics, both hospitals 
Participant characteristics Total  SARS-CoV-2 antibody detected P-value* 
N n % (95% CI) 
Age groups 
(years) 
18-29 1,350 177 13 (11 – 15)  
<0.001 
 30-39 1,617 168 10 (8.9 - 12) 
 40-49 1,515 124 8.2 (6.9 – 9.7) 
 50-59 1,001 77 7.7 (6.1 – 9.5) 
 Over 60 304 30 9.9 (6.8 – 14) 
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Sex Female 4,478 422 9.4 (8.6 – 10)  
 0.013  Male 1,308 154 12 (10 - 14) 
Ethnicity Irish  4,444 384 8.6 (7.8 – 9.5)  
<0.001  Any other white background 551 62 11 (8.7 – 14.2) 
 African and any other black 
background 
113 16 14 (8.3 - 22) 
 Asian background 577 107 19 (16 - 22) 
 Other  101 7 6.9 (2.6 - 15) 
Country of birth* Ireland 4,273 373 8.7 (7.9 – 9.6) 
 
<0.001 
 United Kingdom 344 32 9.3 (6.5 - 13) 
 India 299 54 18 (14 - 31) 
 Philippines 191 47 25 (19 - 31) 
 Poland 72 10 14 (6.9 -24) 
 USA 60 3 5.0 (1.0 - 14) 
 Other  548 57 10 (8.0 - 13) 
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Education Primary 29 4 14 (3.9 - 32)  
0.055  Secondary 684 61 8.9 (6.9 - 11) 
 Third level 2,545 283 11 (9.9 - 12) 
 Post-graduate 2,527 228 9.0 (7.9 - 10) 
Role Admin 803 48 6.0 (4.4 – 7.9) 
<0.001 
 Medical/dental 982 102 10 (8.6 - 13) 
 Nursing/ midwifery 2,064 263 13 (11 -14) 
 Allied health 1,091 73 6.7 (5.3 -8.3) 
 General support 434 33 7.6 (5.3 - 11) 
 Health care assistant 286 50 18 (13 - 22) 
 Other 127 7 5.5 (2.2 - 11) 
Lives with Alone 479 28 5.9 (3.9 – 8.3) 
0.007  With others 5,286 546 10 (9.5 - 11) 
 Missing 22 2 9.1 (1.1 - 29) 
Lives with HCW Yes 1,767 234 13 (12 - 15) <0.001 
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 No 3,919 332 8.5 (7.6 -9.4) 
 Missing 101 10 9.9 (4.9 -18) 





Table 2b. Prevalence of SARS-CoV-2 antibodies by COVID-19 related characteristics, both hospitals 
Participant characteristics Total SARS-CoV-2 IgG detected P-value* 
N n  % (95% CI) 
Contact of a COVID-
19 case 
Yes 1,704 
325 19 (17 - 21) 
<0.001 
 No 249 249 6.1 (5.4 -6.9) 
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 Missing 10 2 167 (2.1 - 48) 
Setting of close 
contact 
Contact at work 
1,495 269 18 (16 - 20) 
0.002 
 Contact outside of 
work 
209 56 27 (21 - 33) 
Workplace exposure Daily contact with 
COVID-19 patients 
902 136 15 (13 - 18) 
<0.001 
 Daily contact with 
patients without 
COVID  
3,245 344 11 (9.6 - 12) 
  No patients contact 1,635 96 5.9 (4.9 – 7.1) 
Previous COVID-19 
like symptoms 
No symptoms 2,876 92 3.2 (2.6 – 3.9) 
<0.001 
 Had symptoms 2,911 484 17 (15 - 18) 
Previous COVID-19 
PCR test Yes 
2,778 474 17 (16 - 19) <0.001 
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 No 3,003 102 3.4 (2.8 – 4.1) 
Previous positive 
COVID-19 PCR test 
Yes 367 350 95.4 (92.7 – 97.3) 
<0.001 
 No 5,414 226 4.2 (3.7 – 4.7) 
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Table 3. Association between risk factors and the presence of SARS-CoV-2 antibodies, both hospitals 
Participant characteristics Unadjusted relative 





Hospital Hospital 2 Ref.   
 Hospital 1 3.7 (3.1 – 4.6) <0.001 3.7 (3.0 - 4.5) <0.001 
Age groups (years) 18-29 1.7 (1.3 – 2.2) <0.001 1.4 (1.1 – 1.9) 0.006 
 30-39 1.4 (1.1 - 1.8) 0.022 1.2 (0.9 – 1.5) 0.217 
 40-49 1.1 (0.8 - 1.4) 0.656 1.0 (0.8 – 1.3) 0.978 
 50-59 Ref.     
 Over 60 1.3 (0.9 -1.9) 0.224 1.4 (0.9 – 2.0) 0.112 
Sex Female Ref.    
 Male 1.3 (1.1 – 1.5) 0.012 1.2 (1.0 – 1.4) 0.046 
Ethnicity Irish  Ref.    
 Any other white background 1.3 (1.0 – 1.7) 0.041 1.3 (1.0 - 1.6) 0.068 
 African and other black 
background 
1.6 (1.0 – 2.7) 
0.037 1.3 (0.8 – 2.0) 0.299 
 Asian background 2.2 (1.8 – 2.6) <0.001 1.3 (1.0 – 1.6) 0.028 
 Other  0.8 (0.4 -1.7) 0.549 0.6 (0.2 – 1.3) 0.177 
Country of birth Ireland Ref.  Did not enter 
 India 2.1 (1.6 – 2.7) <0.001 
 Philippines 2.8 (2.2 – 3.7) <0.001 
 United Kingdom 1.1 (0.8 – 1.5) 0.717 
 Poland 1.6 (0.9 – 2.9) 0.119 
 USA 0.6 (0.2 -1.7) 0.324 
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 Other  1.2 (0.9 – 1. 6) 0.193 
Education Primary 1.5 (0.6 – 3.8) 0.365 Did not enter 
 Secondary 1.0 (0.8 – 1.3) 0.933 
 Third level 1.2 (1.0 - 1.5) 0.013 
 Post-graduate Ref.  
Role Admin Ref.    
 Doctor\Dental 1.7 (1.3 - 2.4) 0.001 1.2 (0.8 – 1.7) 0.327 
 Nursing 2.1 (1.6 – 2.9) <0.001 1.6 (1.1 – 2.2) 0.007 
 HCA 2.9 (2.0 – 4.2) <0.001 2.0 (1.4 – 3.0) 0.001 
 General support 1.3 (0.8 - 2.0) 0.270 0.9 (0.6 – 1.4) 0.687 
 Allied HCW 1.1 (0.8 – 1.6) 0.531 0.9 (0.6 – 1.3) 0.635 
 Other 0.9 (0.4 – 2.0) 0.837 1.0 (0.5 – 2.1) 0.941 
Lives with Alone Ref.    
 With others 1.8 (1.2 – 2.6) 0.002 1.5 (1.0 – 2.1) 0.048 
Lives with HCW No Ref.    
 Yes 1.6 (1.4 -1.8) <0.001 1.3 (1.1 – 1.5) 0.007 
Contact of a COVID-19 
case 
No 
Ref.   
Did not enter 
 Yes 3.1 (2.7 – 3.6) <0.001 
Close contact at work 
** 
No 
1.5 (1.2 – 1.9) 
0.002 Did not enter 
 Yes Ref.   
Workplace exposure to 
COVID-19 patients 
No patient contact 
Ref.  
 
 Daily contact with patients 
without COVID-19 
1.8 (1.5 – 2.3) <0.001 1.4 (1.1 – 1.8) 
0.008 
 Daily contact with COVID-
19 patients 
2.6 (2.0 – 3.3) 
<0.001 1.6 (1.2 – 2.1) 0.002 







Did not enter 
 Yes 5.2 (4.2 – 6.5) <0.001 





Downloaded from https://www.cambridge.org/core. IP address: 78.16.131.208, on 04 May 2021 at 07:55:39, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268821000984
This is an Accepted Manuscript for Epidemiology & Infection. Subject to change during the 
editing and production process. 
DOI: 10.1017/S0950268821000984 
 
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which 
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original 
work is unaltered and is properly cited. The written permission of Cambridge University Press must 















Downloaded from https://www.cambridge.org/core. IP address: 78.16.131.208, on 04 May 2021 at 07:55:39, subject to the Cambridge Core terms of use, available at
